Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0DFSXJ
ADC Name
hu08-vc-6780
Synonyms
hu08 vc-6780
   Click to Show/Hide
Organization
Pfizer Inc.
Drug Status
Investigative
Drug-to-Antibody Ratio
4
Antibody Name
IL13Ralpha2-AB08-v1.0/1.0
  Antibody Info 
Antigen Name
Interleukin-13 (IL13)
  Antigen Info 
Payload Name
hu08-vc-6780 payload
  Payload Info 
Linker Name
hu08-vc-6780 linker
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 61.8
%
CVCL_4885
Prostate carcinoma
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
1.2
ng/mL
CVCL_4885
Prostate carcinoma
Half Maximal Inhibitory Concentration (IC50) 
2.2
ng/mL
CVCL_0132
Amelanotic melanoma
Half Maximal Inhibitory Concentration (IC50) 
> 400
ug/mL
CVCL_0459
Lung large cell carcinoma
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 61.80% Positive IL13 expression (IL13+++/++)
Method Description
Cells were subcutaneously inoculated at a dose of 1,000,000 cells to the right flank region of each female nude mouse (Day 0). On the day 7 of grouping, the antibody-drug conjugate was intravenously administered at doses of 2 mg/kg, Q4d*4 to thetail of each mouse.
In Vivo Model PC3-MM2 CDX model
In Vitro Model Prostate carcinoma PC3-MM2 cells CVCL_4885
Revealed Based on the Cell Line Data
Click To Hide/Show 3 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 1.2 ng/mL Positive IL13 expression (IL13+++/++)
Method Description
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.

   Click to Show/Hide
In Vitro Model Prostate carcinoma PC3-MM2 cells CVCL_4885
Experiment 2 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 2.2 ng/mL Positive IL13 expression (IL13+++/++)
Method Description
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.

   Click to Show/Hide
In Vitro Model Amelanotic melanoma A-375 cells CVCL_0132
Experiment 3 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) > 400 ug/mL Negative IL13 expression (IL13-)
Method Description
The MTS cell proliferation assay was performed as follows: CellTiter 96 Aqueous Non-Radioactive Cell proliferation Kit is used to determine the number of viable cells in cell proliferation assay. Tumor cells are plated at certain seeding densities in sterile 384-well black clear bottom Matrix plates at 40 uL per well and incubated overnight at 37°C in 5% CO2 before assaying.

   Click to Show/Hide
In Vitro Model Lung large cell carcinoma NCI-H460 cells CVCL_0459
References
Ref 1 Anti-il-13 receptor alpha 2 antibodies and antibody-drug conjugates.